Rapid and Sensitive Detection of SARS-CoV-2 Using Clustered Regularly Interspaced Short Palindromic Repeats.
COVID-19
CRISPR
SARS-CoV-2
detection
nucleic acids
Journal
Biomedicines
ISSN: 2227-9059
Titre abrégé: Biomedicines
Pays: Switzerland
ID NLM: 101691304
Informations de publication
Date de publication:
27 Feb 2021
27 Feb 2021
Historique:
received:
06
02
2021
revised:
15
02
2021
accepted:
24
02
2021
entrez:
6
3
2021
pubmed:
7
3
2021
medline:
7
3
2021
Statut:
epublish
Résumé
Rapid and accurate detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is essential for controlling the pandemic of coronavirus disease 2019. Polymerase chain reaction (PCR)-based technique is the standard test for detection of SARS-CoV-2, which, however, requires complicated sample manipulation (e.g., RNA extraction) and is time-consuming. We previously demonstrated that clustered regularly interspaced short palindromic repeats (CRISPR) could precisely detect Human papillomavirus and somatic mutations of Epidermal growth factor receptor gene and Kirsten rat sarcoma viral oncogene homolog gene in plasma. The objective of this study was to develop CRISPR as a rapid test for sensitive detection of SARS-CoV-2. We first combined reverse transcription-isothermal recombinase polymerase amplification and CRSIPR to detect SARS-CoV-2 in genomic RNA of cells infected with the virus. The CRISPR assay with guide RNA against the M gene of SARS-CoV-2 had a sensitivity of 0.1 copies per µL for detection of the virus. We then used the CRSIPR assay to directly analyze raw SARS-CoV-2 samples. The CRISPR assay could sensitively detect SARS-CoV-2 in one hour without RNA extraction. This assay can be performed at a single temperature and with minimal equipment. The results were immediately visualized either by a UV light illuminator or paper strips. The diagnostic value of the test was confirmed in nasopharyngeal swab specimens. Altogether, we have developed a rapid CRISPR test for sensitive detection of SARS-CoV-2.
Identifiants
pubmed: 33673601
pii: biomedicines9030239
doi: 10.3390/biomedicines9030239
pmc: PMC7997215
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Front Public Health. 2020 Jul 29;8:383
pubmed: 32850602
Science. 2018 Apr 27;360(6387):439-444
pubmed: 29449508
Cell. 2020 Aug 20;182(4):812-827.e19
pubmed: 32697968
J Med Virol. 2021 Jan;93(1):448-455
pubmed: 32603515
Science. 2018 Apr 27;360(6387):381-382
pubmed: 29700254
Nature. 2016 Oct 13;538(7624):270-273
pubmed: 27669025
Nature. 2017 Oct 12;550(7675):280-284
pubmed: 28976959
Science. 2017 Apr 28;356(6336):438-442
pubmed: 28408723
Science. 2018 Apr 27;360(6387):444-448
pubmed: 29700266
Lancet. 2020 Feb 22;395(10224):565-574
pubmed: 32007145
Nat Commun. 2019 Jan 22;10(1):212
pubmed: 30670702
Science. 2018 Apr 27;360(6387):436-439
pubmed: 29449511
Nat Commun. 2020 Sep 18;11(1):4711
pubmed: 32948757
Diagnostics (Basel). 2021 Jan 15;11(1):
pubmed: 33467412
Nat Biotechnol. 2020 Jul;38(7):870-874
pubmed: 32300245
Transl Oncol. 2019 Dec;12(12):1566-1573
pubmed: 31634698
Curr Opin Immunol. 2015 Feb;32:36-41
pubmed: 25574773
Nat Rev Microbiol. 2021 Mar;19(3):141-154
pubmed: 33024307
N Engl J Med. 2020 Oct 8;383(15):1492-1494
pubmed: 32937062
Cell Host Microbe. 2021 Jan 13;29(1):23-31.e4
pubmed: 33306985
Cell Discov. 2018 Nov 27;4:63
pubmed: 30510770
Diagnostics (Basel). 2020 Feb 19;10(2):
pubmed: 32093010